{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24430035",
  "DateCompleted": {
    "Year": "2014",
    "Month": "05",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2016",
    "Month": "10",
    "Day": "18"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "rus"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1997-7298",
      "JournalIssue": {
        "Volume": "113",
        "Issue": "12",
        "PubDate": {
          "Year": "2013"
        }
      },
      "Title": "Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova",
      "ISOAbbreviation": "Zh Nevrol Psikhiatr Im S S Korsakova"
    },
    "ArticleTitle": "[Investigation of the effects of cytoflavin on symptoms of depression and autonomic dysfunction in patients with organic depressive disorder].",
    "Pagination": {
      "StartPage": "50",
      "EndPage": "55",
      "MedlinePgn": "50-5"
    },
    "Abstract": {
      "AbstractText": [
        "The present observational study addressed effects of cytoflavin as an adjunctive nootropic therapy in patients with organic depressive disorder (F06.36). 54 female and 46 male in-patients were included into the study. All patients received standard antidepressant therapy (controls) and 48 patients additionally received 2 pills of cytoflavin twice per day. Age, gender distribution, education and severity of depression were equal in cytoflavin and control groups. The follow-up assessment at discharge showed a significantly more pronounced decline in the severity of depression symptoms in patients receiving cytoflavin in comparison with the controls. Importantly, the effect of cytoflavin on the depression symptoms was prominent only in females. Moreover, women receiving cytoflavin demonstrated the more pronounced normalization of autonomic regulation in comparison with control women. The present results allow to recommend cytoflavin in dose 4 pills daily as an adjunctive therapy in female patients with organic depressive disorder."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Kafedra nevrologii i ne\u012drokhirurgii RNIMU im. N.I. Pirogova, Moskva; Nauchno-prakticheski\u012d psikhonevrologicheski\u012d tsentr Departamenta zdravookhraneniia goroda Moskvy."
          }
        ],
        "LastName": "Gudkova",
        "ForeName": "A N",
        "Initials": "AN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Osinovskaia",
        "ForeName": "N A",
        "Initials": "NA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Polunina",
        "ForeName": "A G",
        "Initials": "AG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gekht",
        "ForeName": "A B",
        "Initials": "AB"
      }
    ],
    "PublicationTypeList": [
      "Controlled Clinical Trial",
      "English Abstract",
      "Journal Article",
      "Observational Study"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Russia (Federation)",
    "MedlineTA": "Zh Nevrol Psikhiatr Im S S Korsakova",
    "NlmUniqueID": "9712194",
    "ISSNLinking": "1997-7298"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Combinations"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Nootropic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Succinates"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "cytoflavin"
    },
    {
      "RegistryNumber": "25X51I8RD4",
      "NameOfSubstance": "Niacinamide"
    },
    {
      "RegistryNumber": "7N464URE7E",
      "NameOfSubstance": "Flavin Mononucleotide"
    },
    {
      "RegistryNumber": "86-04-4",
      "NameOfSubstance": "Inosine Diphosphate"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [
        "complications",
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Autonomic Nervous System Diseases"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "complications",
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Combinations"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Flavin Mononucleotide"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Inosine Diphosphate"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Niacinamide"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Nootropic Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sex Factors"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Succinates"
    }
  ]
}